Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $69.91M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.24M
Average 19.76M
GOSS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Gossamer Bio, Inc.NASDAQ: GOSS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $43.07M rose 13.2% year over year, behind the +29.5% change in trailing-twelve-month research & development. Sequentially, it fell 12.0% from the prior quarter. Over 3 fiscal years it compounded at +0.6% a year.
Context
- Research & development amounted to 359.2% of revenue in FY2025, up 238.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +13.2% toward the trailing-twelve-month pace of +29.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 174.09M USD
- Year-over-year change
- +25.7%
- 4-year CAGR
- +0.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 174.09M | +25.7% |
| FY2024 | 2024-12-31 | 138.49M | +2.4% |
| FY2023 | 2023-12-31 | 135.3M | -20.8% |
| FY2022 | 2022-12-31 | 170.92M | +0.4% |
| FY2021 | 2021-12-31 | 170.27M | — |
Research & Development vs competitors
How GOSS compares with its peers on the latest reported figures
- GOSS's LTM Mar 2026 research & development of $186.6M is the 3rd highest of the 9 companies compared; the peer median is $77.47M.
- Its year-over-year change of +29.5% is the 5th highest of 8, against a peer median of +40.8%.
- Research & development amounts to 336.0% of revenue for GOSS, versus a peer median of 125.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $219.98M | +42.7% | +34.6% | 249.3% | |
| LTM Mar 2026 | $186.6M | +29.5% | +0.6% | 336.0% | |
| LTM Mar 2026 | $176.31M | +40.8% | +24.2% | — | |
| LTM Mar 2026 | $96.67M | -53.8% | -0.2% | 166.8% | |
| LTM Mar 2026 | $58.28M | -31.8% | +5.0% | 83.7% | |
| LTM Dec 2025 | $48.42M | — | — | 41.8% | |
| LTM Mar 2026 | $37.44M | +64.5% | +11.3% | — | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| Peer median (excluding GOSS) | $77.47M | +40.8% | +5.0% | 125.3% | |
Competitors are the stored peer set for GOSS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 114.7M | 48.47M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1M |
| Gross Profit | 0 | 0 | 0 | 114.7M | 47.47M |
| Gross Margin | — | — | — | 100.0% | 97.9% |
| Research & Development | 170.27M | 170.92M | 135.3M | 138.49M | 174.09M |
| Selling, General & Admin | 45.78M | 47.61M | 38.46M | 36.13M | 37.63M |
| Operating Expenses | 216.12M | 218.59M | 183.76M | 174.62M | 210.72M |
| Depreciation & Amortization | 5.17M | 4.43M | 4.39M | 4.15M | 1M |
| EBITDA | (209.4M) | (211.07M) | (161.92M) | (39.97M) | (158.47M) |
| EBITDA Margin | — | — | — | -34.8% | -326.9% |
| Operating Income | (216.12M) | (218.59M) | (183.76M) | (59.92M) | (163.25M) |
| Operating Margin | — | — | — | -52.2% | -336.8% |
| Interest Income | 761K | 1.58M | 2M | 1.78M | 1.97M |
| Interest Expense | 19.44M | 13.88M | 13.51M | 11.52M | 10.99M |
| Other Income / Expenses | (17.88M) | (10.79M) | 3.94M | 4.28M | (7.21M) |
| Income Before Tax | (234M) | (229.38M) | (179.82M) | (55.64M) | (170.46M) |
| Pre-Tax Margin | — | — | — | -48.5% | -351.7% |
| Income Tax Expense | 0 | 0 | 0 | 893K | (88K) |
| Net Income | (234M) | (229.38M) | (179.82M) | (56.53M) | (170.37M) |
| Net Margin | — | — | — | -49.3% | -351.5% |
| EPS (Basic) | (3.33) | (2.84) | (0.80) | (0.25) | (0.75) |
| EPS (Diluted) | (3.33) | (2.84) | (1.18) | (0.25) | (0.75) |
| Weighted Avg Shares | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
| Weighted Avg Shares (Diluted) | 74.84M | 84.57M | 225.57M | 226.23M | 228.52M |
Gossamer Bio, Inc.
NASDAQ:GOSS
Intrinsic Alpha fair value
Locked
Current Price
$11.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.